Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide/formoterol MDI in inadequately controlled asthma
NCT05202262Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve 0 to 3 Hours. Started Jan 2022; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05202262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202262.